# US 2013/0274301 A1 · Novel Use of Leflunomide and Malononitrilamides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274301 A1
- Document ID: US20130274301A1
- Status: Published application
- Kind: A1
- Application number: 13/817,800
- Filed: 2011-08-23
- Published: 2013-10-17
- Earliest claimed: 2010-08-24
- Assignees: Al-Giax Pharmaceuticals GmbH
- Inventors: Guido Koopmans; Birgit Hasse; Stefan Mullner
- Web page: https://patentgrep.com/patent/US20130274301A1

## CPC

- A61K 31/42: Oxazoles
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/277: having a ring, e.g. verapamil
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to insulating layers used in electronic devices, the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices.

## Claims

### Claim 1

A compound of the formula (I)
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for use in treating of a central nervous system trauma related disorder.

### Claim 2

A compound of the formula (II)
or a pharmaceutically acceptable salt, solvate, stereoisomer or derivatives thereof for use in treating of a central nervous system trauma related disorder.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein the derivative is a malononitrilamide.

### Claim 4 (depends on 2)

The compound according to claim 2, wherein the derivative is selected from the group consisting of:
i) (1(3-methyl-4-trifluoro methylphenyl-carbamoyl)-2-cyclopropyl-2oxo-propionitrile),
ii) N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-hept-2-en-6-in-carboxylic acidamide, and
iii) 2-cyano-3-cyclopropyl-3-oxo-(4-cyanophenyl)propionamide
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

### Claim 5 (depends on 2)

The compound according to claim 2, wherein the derivative is selected from the group consisting of the following compounds with the formula III to VI:
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

### Claim at position 6

-7. (canceled)

### Claim 8 (depends on 23)

The method according to claim 23, wherein the central nervous system trauma related disorder is complete spinal cord injury, incomplete spinal cord injury, spinal cord contusion, spinal cord compression, spinal cord trauma, spinal injury, paraplegia, quadriplegia, tetraplegia, central cord syndrome, Brown-Séquard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, traumatic brain injury, TBI, brain injury, brain damage, head injury, diffuse axonal injury (DAI), head trauma, brain concussion, brain contusion, subdural hematoma, epidural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, or CNS compression.

### Claim at position 8

-18. (canceled)

### Claim 19 (depends on 8)

The method of claim 8, wherein the central nervous system trauma related disorder is a spinal cord injury or a spinal cord contusion.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A pharmaceutical composition for treating central nervous system-trauma related disorders comprising a therapeutically or prophylactically effective amount of a compound according to claim 1 optionally in admixture with a pharmaceutical acceptable carrier or excipient.

### Claim 22 (depends on 2)

A pharmaceutical composition for treating central nervous system-trauma related disorders comprising a therapeutically or prophylactically effective amount of a compound according to claim 2 optionally in admixture with a pharmaceutical acceptable carrier or excipient.

### Claim 23 (depends on 1)

A method for treating central nervous system-trauma related disorders comprising administering to a patient in need a therapeutically or prophylactically effective amount of a compound according to claim 1 optionally in admixture with a pharmaceutical acceptable carrier or excipient.

### Claim 24 (depends on 2)

A method for treating central nervous system-trauma related disorders comprising administering to a patient in need a therapeutically or prophylactically effective amount of a compound according to claim 2 optionally in admixture with a pharmaceutical acceptable carrier or excipient.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the central nervous system trauma related disorder is complete spinal cord injury, incomplete spinal cord injury, spinal cord contusion, spinal cord compression, spinal cord trauma, spinal injury, paraplegia, quadriplegia, tetraplegia, central cord syndrome, Brown-Séquard syndrome, anterior cord syndrome, conus medullaris syndrome, cauda equina syndrome, traumatic brain injury, TBI, brain injury, brain damage, head injury, diffuse axonal injury (DAI), head trauma, brain concussion, brain contusion, subdural hematoma, epidural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, or CNS compression.

### Claim 26 (depends on 25)

The method of claim 25, wherein the central nervous system trauma related disorder is a spinal cord injury or a spinal cord contusion.
